High Alert
Contraindicated in:
Use Cautiously in:
CV: hypotension (Hepzato only), peripheral edema
Derm: alopecia, DEEP VEIN THROMBOSIS (DVT) (HEPZATO ONLY), pruritus, rash
Endo: menstrual irregularities
F and E: hypokalemia, hypophosphatemia
GI: ↓appetite, ↑liver enzymes (Hepzato only), abdominal pain, constipation, diarrhea, hyperbilirubinemia, mucositis, nausea, vomiting
GU: infertility
Hemat: ↑aPTT, ↑INR, anemia, leukopenia, neutropenia, thrombocytopenia, HEMORRHAGE (HEPZATO ONLY)
MS: ↑troponin I, pain
Neuro: dizziness, fatigue, headache, lethargy
Resp: cough, dyspnea, PULMONARY EMBOLISM (PE) (HEPZATO ONLY)
Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), SECONDARY MALIGNANCY
Drug-drug:

Multiple Myeloma (Palliative Treatment)
Renal Impairment
Multiple Myeloma (Conditioning Treatment)
Unresectable Hepatic Metastases in Patients With Uveal Melanoma
Absorption: IV and intra-arterial administration results in complete bioavailability.
Distribution: Rapidly distributed to tissues.
Half-Life: IV: 1.5 hr; Intra-arterial: 1.1 hr.
(effects on blood counts)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| IV | unknown | 23 wk | 45 wk |
| Intra-arterial | unknown | 1013 days | 23 wk |
NDC Code